Integrated Nanotherapeutics

Integrated Nanotherapeutics (INT) is a Vancouver-based biotechnology company developing antigen-specific immune tolerance therapies using a proprietary multi-cargo mRNA lipid nanoparticle platform. INT’s lead programs target autoimmune diseases, including type 1 diabetes, by reprogramming pathogenic immune responses without systemic immunosuppression.